{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:50:29Z","timestamp":1790351429290,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2009,9,9]],"date-time":"2009-09-09T00:00:00Z","timestamp":1252454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background\u2002<\/jats:bold>\n                    The multikinase inhibitor dasatinib exerts growth\u2010inhibitory effects in patients with imatinib\u2010resistant chronic myeloid leukaemia (CML). In first clinical trials, side effects of dasatinib, 140\u2003mg daily, were reported to be mild and tolerable.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Patients and methods\u2002<\/jats:bold>\n                    We examined the side effect profile in 16 patients with imatinib\u2010resistant CML who received 140\u2003mg dasatinib daily in our center.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results\u2002<\/jats:bold>\n                    Dasatinib produced substantial and sometimes severe or even life\u2010threatening side effects with \u2265\u200310% body weight loss (6\/16 patients), pleural effusions grade II or higher (12\/16) and infectious complications (12\/16), including atypical infections not seen in imatinib\u2010treated patients. One patient developed Epstein\u2013Barr\u2010Virus\u2010positive mucosal leucoplakia, one died from pneumonia caused by pneumocystis carinii and three patients developed a skin\u2010cancer. Most events were recorded within the first 2\u2003years of therapy, only skin tumours developed after the second year. In\n                    <jats:italic>ex vivo<\/jats:italic>\n                    experiments performed in dasatinib\u2010treated patients, transient suppression of IgE\u2010dependent activation of blood basophils and TcR\u2010dependent activation of T\u2010lymphocytes was found. Moreover, in drug\u2010binding studies, dasatinib was found to bind to several key kinase\u2010targets of the immune system including Lyn and Btk, in mast cell, basophil, B\u2010cell and T\u2010cell lines.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion\u2002<\/jats:bold>\n                    Dasatinib acts not only anti\u2010neoplastic in CML but may also act as an immunosuppressive agent when applied at 140\u2003mg daily, and produces frequent pleural effusions and weight loss in advanced CML.\n                  <\/jats:p>","DOI":"10.1111\/j.1365-2362.2009.02206.x","type":"journal-article","created":{"date-parts":[[2009,9,9]],"date-time":"2009-09-09T05:39:10Z","timestamp":1252474750000},"page":"1098-1109","source":"Crossref","is-referenced-by-count":89,"title":["Immunosuppression and atypical infections in CML patients treated with dasatinib at 140\u2003mg daily"],"prefix":"10.1111","volume":"39","author":[{"given":"C.","family":"Sillaber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Rix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Baumgartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Herndlhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tschachler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Superti\u2010Furga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,11,9]]},"reference":[{"key":"e_1_2_8_2_2","first-page":"270","article-title":"Advances in CML","volume":"5","author":"Goldman JM","year":"2007","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2007.01.023"},{"key":"e_1_2_8_4_2","first-page":"1244","article-title":"Emerging stem cell concepts for imatinib\u2010resistant CML: implications for the biology, management, and therapy of the disease","volume":"36","author":"Valent P","year":"2008","journal-title":"Br J Haematol"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2126"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22661"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099480"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.8.18.3257"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-035493"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047266"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046839"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046888"},{"key":"e_1_2_8_14_2","unstructured":"DasJ PatmanabhaR ChenP NorrisDJ DoweykoAMP BarrishJCet\u00a0al.US patent number 006596746\u2010B1. Cyclic protein tyrosine kinase inhibitors. Patent filed July 22 2003."},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-102061"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1328"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200705-715CR"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0329"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-084814"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-104372"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4393"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2007.01892.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-46836-0_5"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005686"},{"key":"e_1_2_8_25_2","first-page":"441","article-title":"Epstein\u2010Barr and human immunodeficiency viruses in acquired immunodeficiency syndrome\u2010related primary central nervous system lymphoma","volume":"141","author":"Morgello S","year":"1992","journal-title":"Am J Pathol"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0732"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(85)90060-8"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(88)90050-1"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0702654104"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9260"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2362.2009.02206.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2362.2009.02206.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T10:32:53Z","timestamp":1697193173000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2362.2009.02206.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,9]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["10.1111\/j.1365-2362.2009.02206.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2362.2009.02206.x","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1570960.1061059","asserted-by":"object"}]},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,9]]}}}